Edition:
India

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

10.17USD
19 Jan 2018
Change (% chg)

$0.59 (+6.16%)
Prev Close
$9.58
Open
$9.77
Day's High
$10.55
Day's Low
$9.50
Volume
183,578
Avg. Vol
58,368
52-wk High
$15.65
52-wk Low
$6.38

Select another date:

Wed, Jan 10 2018

BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer

* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER

BRIEF-Syndax Pharmaceuticals reports Q3 loss per share $0.68

* Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update

BRIEF-Syndax announces $25 million registered direct offering of common stock

* Syndax announces $25 million registered direct offering of common stock

BRIEF-Syndax Pharma enters into license agreement with unit of Allergan

* On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing

BRIEF-‍Syndax announces dosing of first patient in trial of Entinostat for treatment of recurrent breast cancer

* ‍Syndax announces dosing of first patient in pivotal trial of entinostat for treatment of advanced or recurrent breast cancer in Japan by partner kyowa hakko kirin​

BRIEF-Syndax Pharmaceuticals Q2 loss per share $0.70

* Syndax Pharmaceuticals reports second quarter 2017 financial results and provides clinical and business update

Select another date: